在儿科患者中使用MEK和BRAF抑制剂治疗的内分泌作用:三级中心的经验

相关实验视频

Updated: Jun 5, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Arif Hanafi Bin Jalal¹, Harriet Gunn^2,3, Buddhi Gunasekara⁴

¹UCL Medical School, University College London, London, UK.

Journal of neuro-oncology

|December 13, 2024

概括

在患有癌症的儿童中,BRAF和MEK抑制剂可能会导致内分泌问题,如低血和葡萄糖失调. 患有中部无味糖尿病的患者在治疗期间患有低血的风险更高.

科学领域:

儿科瘤学儿科瘤学
内分泌学在内分泌学.
药理学药理学是指药理学的学科.

背景情况:

BRAF和MEK抑制剂向BRAF/MAPK/MEK通路,在各种小儿瘤中至关重要,如低度质瘤.
这些向治疗可以导致副作用,包括管病变和高血糖症,由于途径无处不在.

研究的目的:

用BRAF和MEK抑制剂治疗的儿童内分泌功能障碍的描述.
在这个队列中分析葡萄糖失调和低血糖的发生率.

主要方法:

对55名用达布拉费尼布和特拉美丁尼布治疗的患者的电子数据的回顾性审查 (2019年1月至2022年5月).
评估的结果包括葡萄糖调节失调,低血压 (<135 mmol/l) 和治疗期间血底值.

主要成果:

九名患者患有低血症;三名患者同时患有中部无味糖尿病.
在糖尿病无味症患者 (中位数134 mmol/l) 和没有糖尿病患者 (中位数137 mmol/l) 中观察到统计学上显著的较低血极值.
六名患者出现葡萄糖失调 (例如,胰岛素耐药性,2型糖尿病),四名患者在达布拉芬尼治疗期间患有下丘脑下垂体病变.

结论:

临床医生必须意识到BRAF和MEK抑制剂的潜在内分泌副作用.
在患有先前存在的中枢糖尿病无味症的患者中,需要特别警低血症.
建议在治疗前,治疗期间和治疗后对和葡萄糖水平进行监测.

关键词:

这是一种BRAF抑制剂.低血症是什么意思低血症是什么意思在MAPK/ERK路径中.这是一种MEK抑制剂.儿科内分泌学儿科内分泌学儿科瘤学儿科瘤学

更多相关视频

A Melanoma Patient-Derived Xenograft Model

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...